Navigation Links
Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
Date:7/7/2010

Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance which include Alzheimer's disease.

Madison, Wis (Vocus) July 7, 2010 -- Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance.

“Quincy Bioscience continues to strengthen its position in developing this novel calcium-binding protein as a platform technology,” said Mark Underwood, president of Quincy Bioscience. “The neuron’s ability to manage calcium and maintain homeostasis is fundamental to proper function. Research has proven the cell’s inability to regulate calcium is a key pathophysiological component in many different brain disorders, including Alzheimer’s disease. Based on our ongoing research of aequorin in various health conditions and what we know about the role of calcium in the body, we expect aequorin to be a vital protein in many aspects of healthy aging.”

Aequorin, which comes from a species of jellyfish called Aequorea victoria, is a calcium-binding protein. In humans calcium-binding proteins are utilized to maintain calcium balance which is critical to proper cell function. Aequorin has proven to be neuroprotective in pre-clinical studies performed at the University of Wisconsin-Milwaukee and has shown to be effective at improving aspects of cognition such as spatial working memory and executive function in human studies conducted by Quincy Bioscience.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4235874.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
2. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
3. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
4. Flagship Biosciences Partners with a Leading IHC CLIA Laboratory for Companion Diagnostics Service
5. Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of Alex Leaf Distinguished Scientist Award
6. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
7. Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
8. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
9. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
10. Childrens Hospital Los Angeles oncologist receives $50,000 Hyundai Scholar Award
11. Stamen Medical Systems Receives Medicare Re-Accreditation and The Exemplary Provider Award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
Breaking Medicine Technology: